Enhertu showed substantial clinical activity in patients with HER2 ...
WEBSep 13, 2024 · Enhertu showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases. PUBLISHED 13 September 2024. AstraZeneca and Daiichi Sankyo’s Enhertu achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12.
Enhertu demonstrated a median progression-free survival of 13.2 …
WEBJun 2, 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
ENHERTU® Showed Substantial Clinical Activity in Patients with …
WEBSeptember 13, 2024. Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12. Largest prospective trial of ENHERTU in this patient population.
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · Targeted Therapy Improves Survival for Metastatic “HER2-Low” Breast Cancer. Enhertu expected to become new standard for treating metastatic breast cancer with low HER2 protein levels.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
WEBPUBLISHED 5 April 2024. Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s ENHERTU which showed clinically meaningful responses across a broad range of tumors. ENHERTU now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers.
Enhertu Breast Cancer Drug Results in ‘Unheard-of’ Survival …
WEBJune 7, 2022. The patients had metastatic breast cancer that had been progressing despite rounds of harsh chemotherapy. But a treatment with a drug that targeted cancer cells with laserlike...
ENHERTU - Business Wire
WEBSep 13, 2024 · HER2-Low Metastatic Breast Cancer DESTINY-Breast04 The safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who received ...
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
WEBJul 5, 2022 · In the trial, people with metastatic breast cancer who were treated with the HER2 -targeted drug trastuzumab deruxtecan (Enhertu) lived nearly twice as long without their cancer growing, and lived 6 months longer overall, than those treated with standard chemotherapy.
A New Standard of Care? Enhertu Improves Survival in People …
WEBDec 26, 2022 · Enhertu improves both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.